132 results about "Cholestasis" patented technology

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and / or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and / or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis / fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired / improvable cognitive function.

The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α.4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof.

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

A leveo-potassium magnesium aspartate infusion injection consists of levo-potassium aspartate, levo-magnesium asparatate, osmotic pressure regulator and pH regulator. It is a kind of electrolyte extender for infusion, and has pH value of 5-11.5, high concentration, large dosage, high stability and no pollution. it has wide application range, and is suitable for intravenously guttae to treat arrhythmia caused by various causes, chronic alcoholism fremitus, myocardiopathy as diabetes complication, etc. and applicaltion in heart operation. It is also suitable for acute and chronic hepatitis, intrahepatic cholestasis, and disease of respiratory system, nerve system and metabolic system.

The invention relates to a group of benzene sulfonamido benzamide derivatives, and a preparation method and an application thereof. The research results indicate that the compounds obviously inhibit the apical sodium-dependent bile acid transporter (ASBT) at the cellular level, thereby being expected to be researched and developed to become a clinically effective medicament for treating hyperlipemia and cholestatic diseases.

The invention relates to applications of serum taurochenodeoxycholic acid and chenodeocycholic acid as diagnostic markers in the preparation of medical instruments for diagnosing biliary atresia of newborns. The diagnostic markers of the medical instruments are content ratio of the taurochenodeoxycholic acid and the chenodeocycholic axid in serum. The invention also provides the application of chenodeocycholic acid. The application of diagnostic markers in biliary atresia of the newborns has the advantages that the application of the taurochenodeoxycholic acid and the chenodeocycholic acid as diagnostic markers of biliary atresia is proposed for the firstly time, so that the biliary atresia can be distinguished from other cholestasis diseases of newborns, the best operation time of children can be strived for, and therefore, the operation effect can be improved.

The invention discloses gardenia polysaccharide and an extraction method thereof. The gardenia polysaccharide is prepared from the following raw materials (by mass): 41 to 56 percent of total sugar, 34 to 45 percent of uronic acid and 7 to 10 percent of protein. The preparation method of the gardenia polysaccharide comprises the following steps: crushing a gardenia medicinal material, degreasing,adding water, extracting, precipitating with ethanol, repeatedly freeze-thawing to remove protein, dialyzing, and freeze-drying. The gardenia polysaccharide prepared by the method can improve cholestatic liver injury induced by alpha-naphthalene isothiocyanate (ANIT) and 3, 5-diethoxycarbonyl-1, 4-dihydro-2, 4, 6-trimethylpyridine (DDC), and reduce fibrosis induced by carbon tetrachloride (CCL4).And the liver protection effect of the gardenia polysaccharide is not reported in literatures, which indicates that the gardenia polysaccharide has obvious application prospects in the preparation ofliver protection drugs, especially in the preparation of anti-cholestatic liver injury and anti-hepatic fibrosis drugs.

The present invention relates to a compound medicine formed from diammonium glycyrrhizinate and one or several kinds of halfcystine, glycine, methionine and vitamin B1. Its therapeutic action is extensive, and side effect is low. Said compound medicine can be used for curing the liver diseases of acuter, chronic and virus hepatitises, cirrhosis and fatty liver, etc. and can be used for improving function of liver and cholestasis in the liver. Besides, it also can be used for auxiliary therapy of alcoholism and barbitones and sulfonamides drug poisoning.

Disclosed are compositions and methods for treating cardiovascular disease and reducing the adverse effects induced by the administration of statins. In particular, disclosed is the use of antisense compounds to augment the expression of mirR-33 and associated genetic elements. In particular methods of the treatment of cardiovascular disease and the modulation of miR-33 levels is disclosed as well as treatment of the secondary effects including cholestasis, induced by the administration of statins is disclosed. Also disclosed is the treatment of Benign Recurrent Intrahepatic Cholestasis and reverse cholesterol transport. The disclosed methods and compositions may be practiced separately or co-administered with satins to reduce or treat statin induced secondary effects.

The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholestasis in a subject. The invention also includes a Cholestasis signature database as well as the method of deriving such database.

The present invention relates to compounds of formula (I) wherein wherein R1, R2, R3, R4, R5, R6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and / or prevention of diseases which are modulated by PPARα and / or PPARγ agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis / fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired / improvable cognitive function) and proliferative diseases.

The invention discloses traditional Chinese medicine liquid for treating skin itch and a preparation method, belonging to the field of traditional Chinese medicines. The traditional Chinese medicine liquid disclosed by the invention comprises the following effective components: white loosestrife herb, bunge corydalis herb, jasminum polyanthum, garlic, swamp violet, Indian damnacanthus herb, emblic leafflower leaf, japanese white birch bark, alate senna leaf, Chinese juniper leaf, redfruit actinodaphne root and leaf, calabash, nakedflower beautyberry branchlet and leaf, rhizoma nardostachyos, wadalee-gum-tree and arnica montana. The selected medicinal materials in the traditional Chinese medicine liquid disclosed by the invention are properly compatible and accord with the theories of traditional Chinese medicines and modern medicines; furthermore, the traditional Chinese medicine liquid disclosed by the invention has the effects of clearing heat, disinfecting, eliminating blood-heat and stasis, dispelling the wind, dehumidifying, diminishing swelling and relieving itching, has obvious curative effects on skin itch caused by the systematic diseases, such as inflammatory dermatosis, uremia, primary cholestasis, polycythemia vera and the like, and has the advantages of being short in treatment course, rapid in effect, non-recurrent after healing, safe and free from toxic and side effect; the purpose of treating both symptoms and root causes can be achieved, and therefore, the traditional Chinese medicine liquid for treating skin itch disclosed by the invention is worthy of being widely popularized and applied.

The invention discloses a traditional Chinese medicine composition and a preparation method and the application thereof. The traditional Chinese medicine composition is prepared from eucommia bark, radix scutellariae (preparation), herba artemisiae capillaries, capejasmine (stir-bake), rhubarb, herba hyperici japonica, dittany bark, Tuckahoe, salvia miltiorrhiza and radix curcumae according to certain proportioning by weight and can be prepared to any common peroral dosage type. The traditional Chinese medicine composition has the action of kidney tonify, miscarriage prevention, petechia passing, cholagogic effect, invigorating spleen and eliminating dampness and is safe and effective to treat pregnancy intrahepatic cholestasis, ABO blood group incompatibility, icterus neonatorum, and the like.

Provided is an investigation method for determining liver damage type, using as an indicator the concentration of lithocholic acid (hereinafter abbreviated as LCA) in a biological sample derived from a test subject. Specifically, there is provided an investigation method in which the concentration of LCA in a biological sample taken from a test subject is measured, and using the measured LCA concentration as an indicator, the type of liver damage is determined to be hematocyte damage type, cholestatic type, or a mixed type thereof.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

The invention relates to a composition for improving intrahepatic cholestasis and a preparation method thereof. The composition comprises a coated glycyrrhizinate derivative / butyrin particle, an engelitin-rhubarb anthraquinone compound extract, a capillary wormwood herb extract, quercetin compounds selected from quercetin or dihydroquercetin, and an optional probiotic viable bacteria dry powder preparation. The composition for improving intrahepatic cholestasis provided by the invention has little side effects, and can effectively improve cholestasis symptoms and intestinal internal environment.

A method is provided to measure modulation of bile salt export transport and / or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and / or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and / or formation activity modulation includes but not limited to inhibition, induction, activation and / or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and / or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.

The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.

The invention discloses an application of deoxyschizandrin in preparation of drug for treating cholestasis liver injury. Deoxyschizandrin has molecular formula of C24H32O6 and molecular weight of 416.51, and has the structural formula shown in the description. Mouse liver injury induced by application of excessive lithocholic acid (LCA) is taken as a model. After application of deoxyschizandrin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in serum are significantly lowered, while necrosis degree of liver cells is significantly improved. The results indicate that deoxyschizandrin has treatment effect for liver injury induced by LCA, and can be used for treating cholestasis liver injury clinically.

The invention discloses pharmaceutical composition for post-operative nursing for cholangitis and a preparation method of the pharmaceutical composition. The pharmaceutical composition for post-operative nursing for the cholangitis comprises components in parts by weight as follows: 12-30 parts of p-coumaric acid, 15-32 parts of naringin, 10-28 parts of cordacin, 10-25 parts of a water shield extract, 15-26 parts of mangiferin, 8-18 parts of red halloysite nano-powder, 12-24 parts of limonene, 16-28 parts of eucalyptol, 14-20 parts of chlorogenic acid, 6-12 parts of levamisole hydrochloride, 40-80 parts of a magnesium sulfate solution, 50-100 parts of corn steep liquor, 8-16 parts of potassium sorbate and 13-25 parts of mixed amino acid. Effective components of Chinese herbal medicines are added on the basis of Western medicines, the pharmaceutical composition has effects of resisting bacteria, diminishing inflammations, inhibiting intestinal infection and preventing cholestasis, effectively regulates functions of the liver, the gall bladder and intestines of a patient and improves various anomaly indexes of the body, so that relapse of the cholangitis is prevented, and post-operative body recovery of the patient can be accelerated. The pharmaceutical composition is simple in preparation process and convenient to use and has the great clinical significance.